Pharmacokinetics and pharmacodynamics of a novel extended-release ciprofloxacin in healthy volunteers

Journal of Clinical Pharmacology

Volumn 45, Issue 11, 2005, Pages 1236-1244

  Washington, Carla B ^a   Hou, S Y E ^a   Campanella, Corinne ^b   Hughes, Nicki ^b   Brown, Steven ^c   Berner, Bret ^a  

^a Pharmacokinetics Depomed Inc   (United States)

^b Biovail Contract Research   (Canada)

^c CLINICAL MICROBIOLOGY INSTITUTE   (United States)

Author keywords

Bioavailability; Minimum inhibitory concentrations; Urinary excretion

Indexed keywords

CIPROFLOXACIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG URINE LEVEL; EXTENDED RELEASE FORMULATION; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HUMAN EXPERIMENT; IMMEDIATE RELEASE FORMULATION; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; URINARY EXCRETION; VOLUNTEER;

ADULT; ANTI-INFECTIVE AGENTS; BACTERIA; CIPROFLOXACIN; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED;

EID: 27244442739     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005280542     Document Type: Article

References (22)

1. Davis R, Markham A, Balfour JA. Ciprofloxacin: an updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs. 1996;51:1019-1074.
2. Vance-Bryan K, Guay DR, Rotschafer JC. Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet. 1990;19:434-461.
3. CIPRO (ciprofloxacin hydrochloride) tablets, CIPRO (ciprofloxacin) 5% and 10% oral suspension [package insert]. West Haven, Conn: Bayer Pharmaceuticals; 2004.
4. Harder S, Fuhr U, Beermann D, Staib AH. Ciprofloxacin absorption in different regions of the human gastrointestinal tract: investigations with the hf-capsule. Br J Clin Pharmacol. 1990;30:35-39.
5. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs. 1999;58(suppl 2):29-36.
6. Schentag JJ. Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia. Scand J Infect Dis Suppl. 1991;74:218-234.
7. Lode H, Borner K, Koeppe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis. 1998;27:33-39.
8. Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis. 2003;22:203-221.
9. Dalhoff A. Pharmacodynamics of fluoroquinolones. J Antimicrob Chemother. 1999;43(suppl B):51-59.
10. Aminimanizani A, Beringer P, Jelliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet. 2001;40:169-187.
11. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. 6th ed. Wayne, Pa: National Committee for Clinical Laboratory Standards; 2003.
12. Henry DC, Bettis RB, Riffer E, Haverstock DC, Kowalsky SF, Manning K. Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women. Clin Ther. 2002;24:2088-2104.
13. Waugh J, Keating GM. Ciprofloxacin extended release; in the treatment of urinary tract infections and uncomplicated pyelonephritis [discussion 65-56]. Drugs Aging. 2004;21:55-64.
14. Richard GA, Mathew CP, Kirstein JM, Orchard D, Yang JY. Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens. Urology. 2002;59;334-339.
15. Wagenlehner FM, Wydra S, Onda H, Kinzig-Schippers M, Sorgel F, Naber KG. Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother. 2003;47:3789-3794.
16. Lubasch A, Keller I, Borner K, Koeppe P, Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother. 2000;44:2600-2603.
17. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37:1073-1081.
18. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA. 1998;279:125-129.
19. Peloquin CA, Cumbo TJ, Nix DE, Sands MF, Schentag JJ. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections: impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch Intern Med. 1989;149:2269-2273.
20. Kamberi M, Tsutsumi K, Kotegawa T, et al. Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin. Antimicrob Agents Chemother. 1999;43:525-529.
21. Leigh DA, Tait S, Walsh B. Antibacterial activity of lomefloxacin. J Antimicrob Chemother. 1991;27:589-598.
22. Berner B, Cramer M, Chiang Y, Louie-Helm J. Randomized, double-blind comparison of the safety and efficacy of novel, once-daily extended-release ciprofloxacin in uncomplicated urinary tract infection. J Urology. 2004;171:25.